European Union Gives A Thumbs Up To Johnson & Johnson’s One-Shot Vaccine
The European Union on Thursday authorized the use of the one-dose coronavirus vaccine created by Johnson & Johnson. This is the fourth vaccine to get approval from the EU.
The European Union on 11 March authorized the use of the one-dose coronavirus vaccine created by Johnson & Johnson. Previously, vaccines by Pfizer vaccines have been endorsed by the EU. It is the first one-shot COVID vaccine to be approved. Europe’s drug regulator gave its recommendation earlier on Thursday with the EU Commission giving formal approval later in the day.
The vaccine has several advantages including that it can be stored in most standard refrigerators at temperatures of 2 to 8 degrees Celsius (or roughly 36 to 46 degrees Fahrenheit), making it easier and cheaper to transport and store.
This vaccine by J&J is expected to start getting delivered in one month. Once it starts getting delivered. the shot could greatly support Europe’s struggling immunization program and is the fourth to be approved by the EMA. Two-dose vaccines developed by Pfizer-BioNTech, Moderna and AstraZeneca, and the University of Oxford have also been approved earlier.
The vaccine may be easier to transport and store, but it is not as effective as Pfizer and Moderna’s shots at preventing Covid infection. The clinical trial data from the U.S. has shown J&J’s vaccine is 72% effective at guarding against moderate to severe Covid (although it was found to be less potent in trials elsewhere, giving it overall effectiveness of 66%), compared with about 95% for the other two vaccines.
The Chief Scientific Officer of J&J said that this vaccine will aid in the vaccination drive and will also help in fulfilling needs after there is a shortage of supplies of vaccines like Pfizer. The vaccine can also simplify inoculation as it doesn’t require a second dose. After the approval of the J&J vaccine, vaccination through AstraZeneca was temporarily suspended after complaints of blood clots forming in patients’ bodies.